Oct 01, 2025 • CNBC
SOMEWHAT-BULLISH
Trump's pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers
Pfizer's deal with Trump was a relief to the pharma industry, signaling that drugmakers could strike similar deals that would make them immune to tariffs.
Oct 01, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
WELLESLEY HILLS, Mass., Oct. 01, 2025 ( GLOBE NEWSWIRE ) -- Climb Bio, Inc. ( Nasdaq: CLYM ) , a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the addition of Susan Altschuller, Ph.D., ...
Sep 30, 2025 • Benzinga
SOMEWHAT-BULLISH
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NOVATO, Calif., Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ:RARE ) today announced the appointment of Eric Olson as chief business officer ( CBO ) and executive vice president effective September 22, 2025, following the planned retirement of Thomas Kassberg.
Sep 30, 2025 • GlobeNewswire
NEUTRAL
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
NOVATO, Calif., Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) today announced the appointment of Eric Olson as chief business officer ( CBO ) and executive vice president effective September 22, 2025, following the planned retirement of Thomas Kassberg.
Sep 29, 2025 • Benzinga
SOMEWHAT-BULLISH
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide - X4 Pharmaceuticals ( NASDAQ:XFOR ) , Altimmune ( NASDAQ:ALT )
Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises